BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yuan G, Cheng X, Li Q, Zang M, Huang W, Fan W, Wu T, Ruan J, Dai W, Yu W, Chen M, Guo Y, Hu X, Chen J. Safety and Efficacy of Camrelizumab Combined with Apatinib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Multicenter Retrospective Study. Onco Targets Ther 2020;13:12683-93. [PMID: 33328740 DOI: 10.2147/OTT.S286169] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Xie Q, Liu H, Guo Z, Wu Y, He G, Cai L, Pan M, Fu S. Case Report: One-Year Delay in the Effect of Conversion Surgery Therapy for Advanced Hepatocellular Carcinoma After Systemic Therapy. Front Mol Biosci 2022;8:810251. [DOI: 10.3389/fmolb.2021.810251] [Reference Citation Analysis]
2 Liu J, Li Z, Zhang W, Lu H, Sun Z, Wang G, Han X. Comprehensive Treatment of Trans-Arterial Chemoembolization Plus Lenvatinib Followed by Camrelizumab for Advanced Hepatocellular Carcinoma Patients. Front Pharmacol 2021;12:709060. [PMID: 34733154 DOI: 10.3389/fphar.2021.709060] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Liu HT, Jiang MJ, Deng ZJ, Li L, Huang JL, Liu ZX, Li LQ, Zhong JH. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges. Front Oncol 2021;11:737497. [PMID: 34745958 DOI: 10.3389/fonc.2021.737497] [Reference Citation Analysis]
4 Yuan G, Li R, Li Q, Hu X, Ruan J, Fan W, Wang J, Huang W, Zang M, Chen J. Interaction between hepatitis B virus infection and the efficacy of camrelizumab in combination with apatinib therapy in patients with hepatocellular carcinoma: a multicenter retrospective cohort study. Ann Transl Med 2021;9:1412. [PMID: 34733964 DOI: 10.21037/atm-21-3020] [Reference Citation Analysis]
5 Pan D, Liu D, Liang L, Shen T, Shi C, Qin H. Treatment Response, Survival Benefit and Safety Profile of PD-1 Inhibitor Plus Apatinib Versus Apatinib Monotherapy in Advanced Colorectal Cancer Patients. Front Oncol 2022;12:863392. [PMID: 35664730 DOI: 10.3389/fonc.2022.863392] [Reference Citation Analysis]
6 Luo YC, Lu HL, Song WL, Xuan FF. Multidisciplinary treatment of advanced hepatocellular carcinoma with severe arterioportal shunt: a case report. J Int Med Res 2021;49:3000605211024840. [PMID: 34250825 DOI: 10.1177/03000605211024840] [Reference Citation Analysis]
7 Yao J, Zhu X, Wu Z, Wei Q, Cai Y, Zheng Y, Hu X, Hu H, Zhang X, Pan H, Zhong X, Han W. Efficacy and safety of PD-1 inhibitor combined with antiangiogenic therapy for unresectable hepatocellular carcinoma: A multicenter retrospective study. Cancer Med 2022. [PMID: 35403359 DOI: 10.1002/cam4.4747] [Reference Citation Analysis]
8 Yuan G, Xie F, Song Y, Li Q, Li R, Hu X, Zang M, Cheng X, Lu G, Huang J, Fan W, Rong X, Sun J, Chen J. Hepatic Tumor Stiffness Measured by Shear Wave Elastography Is Prognostic for HCC Progression Following Treatment With Anti-PD-1 Antibodies Plus Lenvatinib: A Retrospective Analysis of Two Independent Cohorts. Front Immunol 2022;13:868809. [PMID: 35757765 DOI: 10.3389/fimmu.2022.868809] [Reference Citation Analysis]
9 Yang Y, Li J, Till BG, Wang J, Zhang B, Wang H, Huang H, Li T, Gao Q, Li H, Wang Z. Toxic Epidermal Necrolysis-Like Reaction Following Combination Therapy With Camrelizumab and Apatinib for Advanced Gallbladder Carcinoma. Front Oncol 2021;11:728253. [PMID: 34778042 DOI: 10.3389/fonc.2021.728253] [Reference Citation Analysis]
10 Ma N, Qiao H, Tao H, Gan X, Shan Z, Chen X, Zhou X. Treatment response, survival, and safety profile of camrelizumab plus apatinib regimen as third-line treatment in metastatic gastric cancer patients. Clinics and Research in Hepatology and Gastroenterology 2022. [DOI: 10.1016/j.clinre.2022.101962] [Reference Citation Analysis]